Chimeric antigen receptor (CAR)-T cell therapy has achieved successful outcomes against
hematological malignancies and provided a new impetus for treating solid tumors. However …

Macrophages are the dominant leukocyte population found in the tumor microenvironment.
Accumulating evidence suggests that these tumor-associated macrophages (TAMs) actively …

Cancer-associated thrombocytosis has long been linked to poor clinical outcome, but the
underlying mechanism is enigmatic. We hypothesized that platelets promote malignancy …

Adoptive cellular immunotherapy (ACT) employing engineered T lymphocytes expressing
chimeric antigen receptors (CARs) has demonstrated promising antitumor effects in …

Pancreatic ductal adenocarcinoma (PDAC) elicits a dense stromal response that blocks
vascular access because of pericyte coverage of vascular fenestrations. In this way, the …

T cells engineered to express chimeric antigen receptors (CARs) have shown remarkable
success in treating B-cell malignancies, reflected by multiple US Food and Drug …

A chimeric antigen receptor (CAR) that responds to transforming growth factor beta (TGF‐β)
enables the engineering of T cells that convert this immunosuppressive cytokine into a …

The tumor microenvironment (TME) is shaped by dynamic metabolic and immune
interactions between precancerous and cancerous tumor cells and stromal cells like …

Background: Chimeric antigen receptor (CAR)-modified T cells have successfully harnessed
T cell immunity against malignancies, but they are by no means the only cell therapies in …

The identification of tumor-specific antigens and the immune responses directed against
them has instigated the development of therapies to enhance antitumor immune responses …